Sulthiame

DB08329ApprovedSmall molecule

Sulthiame is a carbonic anhydrase inhibitor used primarily in benign focal epilepsies of childhood that may be useful as an adjunct therapy in a variety of other refractory epilepsies. A medication used primarily to treat specific kinds of epilepsy.

Chemical structure of Sulthiame
Mechanism
Curator reviewed · 1 reference
Formula / weight
C10H14N2O4S2 · 290.359 g/mol (avg)
Also known as
Sultiame
Code names
Bayer A-168 · R-594 · RIKER-594 · RP-10284

Resolves to

Compound
UNIII00Q766CZ2CAS61-56-3ChEMBLCHEMBL328560ChEBI32171PubChem5356
Clinical / RWD
RxNorm10240ATCG01AE10ATCN03AX03
Structure
InChIKeyHMHVCUVYZFYAJI-UHFFFAOYSA-NSMILESNS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
Targets
P00918CA2

What you can answer from here — as of September 16, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
918Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
5Marketed productsAcross 1 country and 2 labellers
Sign in
2ATC codesIncluding every combination product, plus 11 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sulthiame, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In